Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) have been given a consensus rating of “Buy” by the eleven analysts that are presently covering the firm, Marketbeat.com reports.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback